Mesoblast's Ryoncil receives J-Code for broader reimbursement

Mesoblast Limited reported today that Ryoncil (remestemcel-L-rknd) has been assigned a specific Healthcare Common Procedure Coding System (HCPCS) J-Code (J3402) by United States Medicare & Medicaid Services (CMS). This J-Code became active for billing and reimbursement on October 1, 2025, facilitating broader patient access and streamlined billing for the product.

Ryoncil is the first FDA-approved mesenchymal stromal cell (MSC) product for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD). The permanent J-Code provides a clear billing pathway for Medicaid, and commercial payers are expected to update their coverage systems accordingly. Healthcare providers can begin using J3402 for claims submitted on or after October 1, 2025.

Mesoblast holds an extensive global intellectual property portfolio with over 1,000 granted patents or applications, providing commercial protection through to at least 2041. The company's proprietary manufacturing processes ensure industrial-scale, cryopreserved, off-the-shelf cellular medicines with defined pharmaceutical release criteria are readily available.